NICE has announced today, its decision not to recommend olaparib for women with advanced ovarian cancer who had previously responded to platinum chemotherapy for six months or longer.

The study findings could help predict which patients will develop resistance to PARP inhibitors and allow doctors to alter treatment at the earliest possible opportunity.

The Institute of Cancer Research, London, strongly welcomes the news that olaparib has been approved by the US Food and Drug Administration (FDA) for patients with advanced breast cancer.